Expression of DMBT1 in Colorectal Cancer Patients

Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02901600

Acronym

DMBT1

Enrollment

145

Registered

2016-09-15

Start date

2013-06-30

Completion date

2015-11-30

Last updated

2016-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, DMBT1 Protein, Human

Keywords

DMBT1 expression, Colorectal cancer

Brief summary

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease. Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.

Interventions

OTHERDetection of the expression of DMTB1 by immunohistochemistry

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* for colon cancer: patients surgically treated for colorectal cancer at the Group of hospitals of the Catholic Institute of Lille. * for adenomatous polyps : patients treated for adenomatous polyps at the Group of hospitals of the Catholic Institute of Lille. * for controls: patients surgically treated for diverticular disease at the Group of hospitals of the Catholic Institute of Lille.

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Semi-quantitative determination of the histological expression of DMBT1	at baseline	The expression of DMTB1 will be determined by observation of the slides after immunohistochemistry using an anti-DMBT1 antibody
Determination of the histological localisation of DMBT1	at baseline	The localisation of DMTB1 will be determined by observation of slides after immunohistochemistry using an anti-DMBT1 antibody

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026